IONS secures EU approval for Dawnzera in hereditary angioedema, after FDA clearance in the United States in August last year.

Takhzyro (lanadelumab-flyo) is a biologic medicine used to prevent hereditary angioedema (HAE) attacks in people who are 2 years or older. During an HAE attack, swelling under the skin happens in ...

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001) All secondary efficacy endpoints met (p<0.0001), including End of ...

The European Medicines Authority’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for a new drug to treat hereditary angioedema (HAE).

Ionis Pharma & Otsuka’s donidalorsen gets approval in European Union for hereditary angioedema: Carlsbad, California Saturday, January 24, 2026, 13:00 Hrs [IST] Ionis Pharmaceut ...

Good day and thank you for standing by. Welcome to the RAPIDe-3 topline data webcast. [Operator Instructions] I would now like to hand the conference over to your speaker, Maggie, please go ahead.

Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026Preparation of NDA ...

Interim results from KONFIDENT-KID show sebetralstat enables early, effective, safe treatment of HAE attacks in pediatric population and reveal higher attack frequency than previously believed ...

Optimal care for female and pediatric patients with hereditary angioedema (HAE) requires consideration of several population-specific issues. For women, these include menstruation, contraception, ...

Like angioedema in general, hereditary angioedema (HAE) is characterized by subcutaneous or submucosal edema that is nonpruritic — ie, does not itch — and nonpitting — ie, does not leave an ...